World Journal of Clinical Cases, Journal Year: 2025, Volume and Issue: 13(16)
Published: Feb. 10, 2025
BACKGROUND Pancreatic cancer (PC) is a highly malignant tumor that resistant to chemotherapy, radiotherapy and immunotherapy. Combination chemotherapy regimens are the standard first-line for metastatic disease, with median survival < 12 months. Although recurrent genomic alterations such as BRAF V600E mutation have been reported in PC, evidence supporting clinical effectiveness of molecularly guided targeted therapies limited. CASE SUMMARY We report case 33-year-old male who was referred our department weight loss 5 kg 2 months, anorexia abdominal pain. Imaging showed extensive lesions involving pancreas, liver, bones, muscles lymph nodes accompanied by elevated carbohydrate antigen 19-9 (CA19-9) carcinoembryonic (CEA). Biopsy yielded diagnosis PC. Treatment gemcitabine nab-paclitaxel initiated, but disease progressed months even though patient’s general condition improved. Molecular testing revealed presence mutation. Dabrafenib/trametinib combination therapy introduced, patient treated decrease CA19-9 CEA levels, he died after treatment. CONCLUSION infrequent This highlights significance molecular profiling patients especially high burden.
Language: Английский